Literature DB >> 16928812

A retroviral expression system based on tetracycline-regulated tricistronic transactivator/repressor vectors for functional analyses of antiproliferative and toxic genes.

Michael J Ausserlechner1, Petra Obexer, Andrea Deutschmann, Kathrin Geiger, Reinhard Kofler.   

Abstract

Establishment of stably transfected mammalian cells with conditional expression of antiproliferative or proapoptotic proteins is often hampered by varying expression within bulk-selected cells and high background in the absence of the inducing drug. To overcome such limitations, we designed a gene expression system that transcribes the tetracycline-dependent rtTA2-M2-activator, TRSID-silencer, and selection marker as a tricistronic mRNA from a single retroviral vector. More than 92% of bulk-selected cells expressed enhanced green fluorescent protein or luciferase over more than three orders of magnitude in an almost linear, dose-dependent manner. To functionally test this system, we studied how dose-dependent expression of p27(Kip1) affects proliferation and viability of SH-EP neuroblastoma cells. Low to moderate p27(Kip1) expression caused transient G(0)-G(1) accumulation without reduced viability, whereas high p27(Kip1) levels induced significant apoptosis after 72 hours. This proves that this expression system allows concentration-dependent analysis of gene function and implicates p27(Kip1) as a critical regulator of both proliferation and apoptosis in SH-EP neuroblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928812     DOI: 10.1158/1535-7163.MCT-05-0500

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  13 in total

1.  Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice.

Authors:  Karoline Lipnik; Elisabeth Naschberger; Nathalie Gonin-Laurent; Petra Kodajova; Helga Petznek; Stefanie Rungaldier; Simonetta Astigiano; Silvano Ferrini; Michael Stürzl; Christine Hohenadl
Journal:  Mol Med       Date:  2010-02-05       Impact factor: 6.354

2.  BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.

Authors:  J Hagenbuchner; U Kiechl-Kohlendorfer; P Obexer; M J Ausserlechner
Journal:  Oncogene       Date:  2015-07-06       Impact factor: 9.867

3.  Hyperactivation of the mammalian degenerin MDEG promotes caspase-8 activation and apoptosis.

Authors:  Ji-An Pan; Yongjun Fan; Rajesh Kumar Gandhirajan; Muniswamy Madesh; Wei-Xing Zong
Journal:  J Biol Chem       Date:  2012-12-13       Impact factor: 5.157

4.  The interferon stimulated gene 54 promotes apoptosis.

Authors:  Marcin Stawowczyk; Sarah Van Scoy; K Prasanna Kumar; Nancy C Reich
Journal:  J Biol Chem       Date:  2010-12-29       Impact factor: 5.157

5.  Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition.

Authors:  Yongjun Fan; Kathleen G Dickman; Wei-Xing Zong
Journal:  J Biol Chem       Date:  2009-12-17       Impact factor: 5.157

6.  The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.

Authors:  Judith Hagenbuchner; Michael J Ausserlechner; Verena Porto; Reinhard David; Bernhard Meister; Martin Bodner; Andreas Villunger; Kathrin Geiger; Petra Obexer
Journal:  J Biol Chem       Date:  2010-01-05       Impact factor: 5.157

7.  The cell senescence inducing gene product MORF4 is regulated by degradation via the ubiquitin/proteasome pathway.

Authors:  Kaoru Tominaga; Emiko Tominaga; Michael J Ausserlechner; Olivia M Pereira-Smith
Journal:  Exp Cell Res       Date:  2009-09-19       Impact factor: 3.905

8.  p16INK4A sensitizes human leukemia cells to FAS- and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2.

Authors:  Petra Obexer; Judith Hagenbuchner; Martina Rupp; Christina Salvador; Markus Holzner; Martin Deutsch; Verena Porto; Reinhard Kofler; Thomas Unterkircher; Michael J Ausserlechner
Journal:  J Biol Chem       Date:  2009-09-08       Impact factor: 5.157

9.  Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.

Authors:  Frédéric R Santer; Holger H H Erb; Su Jung Oh; Florian Handle; Gertrud E Feiersinger; Birgit Luef; Huajie Bu; Georg Schäfer; Christian Ploner; Martina Egger; Jayant K Rane; Norman J Maitland; Helmut Klocker; Iris E Eder; Zoran Culig
Journal:  Oncotarget       Date:  2015-03-20

10.  A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration.

Authors:  Judith Hagenbuchner; Ursula Kiechl-Kohlendorfer; Petra Obexer; Michael J Ausserlechner
Journal:  Oncotarget       Date:  2013-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.